Since 2013, Daniel Pinschewer serves as a full professor of Virology at the University of Basel, Switzerland.  After graduating from the University of Zurich medical school in the year 2000 he trained as postdoctoral fellow in molecular virology at The Scripps Research Center, and in immunology at the University of Zurich. Prior to his current appointment he was an associate professor of immunology at the University of Geneva (2007-2013).

In recent years, his academic research and contributions to science have focused on the study of B cell responses to and their subversion by chronic viral infection, on the reverse engineering of arenaviruses for vectorized vaccine delivery and on the role of alarmins in protective antiviral T cell responses.

Daniel Pinschewer  is the recipient of career awards from the European Research Council and from the Swiss National Science Foundation. Patented discoveries made in my laboratory represent the technological basis of the vaccine and immunotherapy company HOOKIPA Pharma Inc. (Nasdaq HOOK), which he has co-founded. National and international honors received include the Georges-Köhler-Prize of the German Society for Immunology and the Loeffler-Frosch-Prize of the Society for Virology, the Debiopharm Group Life Sciences Award, the Pfizer Research Prize and the Prix Leenaards.